Multiple myeloma is the second most common blood cancer in New Zealand with higher incidence in Māori and Pacific Island populations. It remains an incurable disease but the rapidly changing treatment landscape has led to improved outcome. In response to recent changes in funding of anti-myeloma therapy in New Zealand, the New Zealand Myeloma Interest Group has reviewed the latest literature and updated the treatment pathway of transplant-eligible patients with newly diagnosed multiple myeloma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
multiple myeloma
12
transplant-eligible patients
8
patients newly
8
newly diagnosed
8
diagnosed multiple
8
consensus statement
4
statement treatment
4
treatment transplant-eligible
4
myeloma
4
zealand
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!